Moderna and Merck's Cancer Vaccine Breakthrough: A Century of Failures Overcome
Moderna and Merck have achieved a significant breakthrough in cancer vaccine development after a century of failures. The companies' collaboration has led to a successful trial of their mRNA-based cancer vaccine, marking a major milestone in the fight against cancer.
The breakthrough was announced on August 30, 2026, by Reuters, citing the companies' joint effort to create an effective and safe cancer treatment. According to Stephane Bancel, CEO of Moderna, he received a call celebrating the news while dining at a Lebanese restaurant on August 13.
The mRNA-based technology used in the vaccine has shown promising results in treating various types of cancer, including melanoma and lung cancer. The companies' collaboration marks a significant shift towards using mRNA-based vaccines for cancer treatment, which could potentially lead to more effective and targeted therapies.